Welcome to LookChem.com Sign In|Join Free
  • or
Carbamic acid, [1-(aminocarbonyl)-5-[[(phenylmethoxy)carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester, (R)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

106326-22-1

Post Buying Request

106326-22-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

106326-22-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 106326-22-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,3,2 and 6 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 106326-22:
(8*1)+(7*0)+(6*6)+(5*3)+(4*2)+(3*6)+(2*2)+(1*2)=91
91 % 10 = 1
So 106326-22-1 is a valid CAS Registry Number.

106326-22-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name BOC-Lys(Z)-NH2

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:106326-22-1 SDS

106326-22-1Relevant academic research and scientific papers

Reconstitution of peptidoglycan cross-linking leads to improved fluorescent probes of cell wall synthesis

Lebar, Matthew D.,May, Janine M.,Meeske, Alexander J.,Leiman, Sara A.,Lupoli, Tania J.,Tsukamoto, Hirokazu,Losick, Richard,Rudner, David Z.,Walker, Suzanne,Kahne, Daniel

, p. 10874 - 10877 (2014)

The peptidoglycan precursor, Lipid II, produced in the model Gram-positive bacterium Bacillus subtilis differs from Lipid II found in Gram-negative bacteria such as Escherichia coli by a single amidation on the peptide side chain. How this difference affects the cross-linking activity of penicillin-binding proteins (PBPs) that assemble peptidoglycan in cells has not been investigated because B. subtilis Lipid II was not previously available. Here we report the synthesis of B. subtilis Lipid II and its use by purified B. subtilis PBP1 and E. coli PBP1A. While enzymes from both organisms assembled B. subtilis Lipid II into glycan strands, only the B. subtilis enzyme cross-linked the strands. Furthermore, B. subtilis PBP1 catalyzed the exchange of both d-amino acids and d-amino carboxamides into nascent peptidoglycan, but the E. coli enzyme only exchanged d-amino acids. We exploited these observations to design a fluorescent d-amino carboxamide probe to label B. subtilis PG in vivo and found that this probe labels the cell wall dramatically better than existing reagents.

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

Lohou, Elodie,Sasaki, N. André,Boullier, Agnès,Sonnet, Pascal

, p. 702 - 722 (2016/07/26)

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in?vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 106326-22-1